However, in the ICAM-1 targeted CARTs, the KD of LFA binding ICAM-1 is at micromolar (KD=20μM) to generate the most effective antitumor effects with reduced toxicity in preclinical tumor model (171). This evidence concerns the gene ICAM1 and neoplasm.